Welcome to our dedicated page for Xortx Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on Xortx Therapeutics stock.
XORTX Therapeutics Inc. develops therapies for gout and progressive kidney disease, with programs that include XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections, and XRx-225 for Type 2 diabetic nephropathy. The company also holds the VB4-P5 kidney anti-fibrotic program, a pre-IND asset targeting rare and prevalent forms of kidney disease.
Company announcements cover clinical and preclinical pipeline development, acquired kidney-disease assets, share consolidations, Nasdaq and TSX Venture Exchange listing matters, annual meeting results, board elections, auditor appointments, stock option plan approvals, and other governance actions tied to its public-company status.
XORTX Therapeutics (NASDAQ:XRTX) priced a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share for expected gross proceeds of US$5 million before fees and expenses.
The pre-funded warrants are immediately exercisable at US$0.0001 and the offering is expected to close on or about May 15, 2026, subject to customary conditions and regulatory approvals.
XORTX (NASDAQ: XRTX) received a Nasdaq letter of compliance on April 20, 2026, curing a prior deficiency under Nasdaq Rule 5550(a)(2) that requires a US$1.00 minimum bid price.
Following a 1-for-5 reverse share split implemented April 6, 2026, the company’s shares traded at or above US$1.00 for 10 consecutive trading days, meeting the requirement on April 17, 2026.
XORTX (NASDAQ: XRTX) announced it closed the acquisition of the Vectus kidney anti-fibrotic asset, VB4-P5, on April 13, 2026 for an aggregate purchase price of US$3.0 million.
The Program includes a pre-IND small-molecule NCE, associated patent family, regulatory documentation and manufacturing data. Consideration: 154,544 common shares at US$3.5432 and 692,150 pre-funded warrants at US$3.5431 (exercise US$0.0001), warrants expire April 13, 2031 and include a 9.99% ownership cap. TSXV has conditionally approved listing of shares; common shares issued without a hold period under applicable Alberta rule.
XORTX (NASDAQ: XRTX) confirmed a 1-for-5 share consolidation will take effect on April 6, 2026. According to the company, the consolidation received required approvals from the TSX Venture Exchange and Nasdaq.
The move replaces every five old common shares with one new common share and will adjust the company’s issued and outstanding share count on the effective date.
XORTX (NASDAQ: XRTX) announced results of its annual and special meeting held March 24, 2026. Approximately 2,407,148 common shares were represented, about 35% of outstanding shares. All matters presented were approved, including election of five directors, auditor appointment, reapproval of the stock option plan, and approval of a share consolidation.
Detailed voting results are available in the Report of Voting Results filed on the company’s SEDAR+ profile.
XORTX (NASDAQ: XRTX) announced a change to the effective date of its previously disclosed share consolidation from March 27, 2026 to April 6, 2026. The consolidation remains a 1-for-5 share consolidation and is still subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.
The company attributed the change to timing considerations and confirmed the consolidation will only proceed after receipt of all required exchange approvals.
XORTX (NASDAQ: XRTX) approved a one-for-five share consolidation effective March 27, 2026, reducing issued and outstanding common shares from 6,962,218 to approximately 1,392,444, subject to rounding. The action is intended to satisfy Nasdaq’s $1.00 continual listing requirement and a 10-day price condition by April 13, 2026.
No name change will occur. Fractional post-consolidation shares will be cancelled if under one-half or rounded up if one-half or greater; no cash will be paid for fractions. Convertible securities will be proportionately adjusted. Trading will resume under XRTX with new CUSIP 98420Q405.
XORTX (NASDAQ: XRTX) announced that shareholders approved a share consolidation at the March 24, 2026 annual meeting, authorizing up to a 5-for-1 consolidation to be completed within one year.
The move aims to meet NASDAQ’s continued listing requirement that shares trade above $1.00 (including a 10-day condition by April 13, 2026). Prior to consolidation there are 6,962,218 issued common shares; post-consolidation outstanding shares are approximately 1,392,443, subject to fractional rounding rules. The Consolidation remains subject to TSXV approval and will begin trading post-consolidation on a date set with the TSXV.
XORTX (NASDAQ: XRTX) announced three substitute director nominees — George Scorsis, Richard Grieve and Mika Grasso — to be proposed at its Annual and Special Meeting on March 24, 2026. The appointment is a condition of a significant financing currently under negotiation and subject to TSXV approval; if financing fails, the nominees will resign and vacancies will be filled later. Proxies in favour of management will be voted for the New Nominees unless shareholders instruct otherwise. Shareholders were mailed meeting materials on March 2, 2026 and the proxy deadline is March 20, 2026. Voting assistance is available through Laurel Hill Advisory Group.
XORTX (NASDAQ: XRTX) filed and mailed its Meeting Materials for the Annual and Special Meeting of shareholders. The mailing occurred on March 2, 2026, registration record date is Feb 20, 2026, proxy deadline is March 20, 2026 at 10:00 a.m. Calgary Time, and the Meeting is set for March 24, 2026.
Shareholders will vote to elect five directors, appoint the auditor, approve the stock option plan, and consider an articles amendment to consolidate common shares up to five (5) pre-consolidation for one (1) post-consolidation. The Board unanimously recommends voting FOR all items.